Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Adam Sinding Steensberg M.D. | President & CEO | 3.11M | -- | 1974 |
| Ms. Henriette Wennicke | EVP & CFO | 1.37M | -- | 1983 |
| Mr. Ivan Mourits Moller | Executive VP & COO | -- | -- | 1972 |
| Mr. Ravinder Singh Chahil | EVP & General Counsel | -- | -- | 1968 |
| Ms. Christina Sonnenborg Bredal | Executive VP & Chief People Officer | -- | -- | 1985 |
| Dr. Jens Damsgaard Mikkelsen M.D. | Head of Molecular Pharmacology | -- | -- | -- |
| Dr. David M. Kendall M.D. | Executive VP, Chief Medical Officer & Head of R&D | -- | -- | 1961 |
| Mr. Eric Cox | Executive VP & Chief Commercial Officer | -- | -- | 1967 |
| Miriam I. Katz | Assistant Secretary | -- | -- | -- |
| Dr. Anna Krassowska Ph.D. | Vice President of Investor Relations & Corporate Communications | -- | -- | -- |
Zealand Pharma A/S
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 335
Description
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S was incorporated in 1997 and is based in Søborg, Denmark.
Corporate Governance
Upcoming Events
May 7, 2025 at 11:00 PM UTC
Zealand Pharma A/S Earnings Date
Recent Events
September 30, 2022 at 12:00 AM UTC
15F-12B: Notice of termination by a Foreign Private Issuer of a class of equity securities under Section 12(b)
September 20, 2022 at 12:00 AM UTC
25: Notification filed by issuer to voluntarily withdraw a class of securities from listing and registration on a national securities exchange